Kaken, Valeant Pharmaceuticals sales and marketing update

Valeant disclosed in its 3Q12 earnings call that it expanded its deal with Kaken for IDP-108. Valeant now has global commercialization rights to IDP-108 excluding Japan, China, Taiwan and South Korea...